Immuno-Oncology
The future of CAR-T therapy in lymphoma, addressing the risk of secondary malignancy & the optimal sequencing of these agents with bispecific antibodies
Immunotherapeutic approaches, including CAR T-cells and bispecific antibodies, have become well-established in later lines of non-Hodgkin lymphoma (NHL) treatment. CAR…
Date: 16th May 2024
iwMyeloma 2024 Session I: approaching bone disease, clinical trial updates & the value of MRD as an endpoint in trials
The 17th International Workshop on Multiple Myeloma (iwMyeloma 2024) was held recently in Miami, FL, and brought together experts from…
Date: 10th May 2024
Managing anemia in MF, key emerging trials in the UK, and approaching young patients with MPNs
Myelofibrosis (MF) is a hematologic malignancy that causes progressive bone marrow fibrosis and presents with other clinical manifestations, including anemia…
Date: 3rd May 2024
Exploring the possibility of early interception in smoldering myeloma: novel agents, challenges & advances in risk stratification
Smoldering multiple myeloma (SMM) and monoclonal gammopathy of undetermined significance (MGUS) are two well-known precursor conditions to multiple myeloma, and the…
Date: 4th April 2024
Monoclonal B-cell lymphocytosis: classification, biology and exploring the possibility of early interception
Monoclonal B-cell lymphocytosis (MBL) is a condition characterized by the presence of an abnormal increase in B lymphocytes in the…
Date: 22nd March 2024
The impact of CAR-T therapy on the myeloma treatment landscape, patient selection for CAR-T & the evolving role of autoSCT
The introduction of CAR-T therapy has revolutionized the myeloma treatment landscape, offering a promising therapeutic approach for patients with relapsed/refractory…
Date: 15th March 2024
Diagnosing amyloidosis, currently available therapies & the importance of cardio-oncology
While there have been advances in the treatment and management of amyloidosis in recent years, diagnosis remains a challenge due…
Date: 7th March 2024
Addressing the importance of lymphodepletion, factors contributing to ICAHT & the cost effectiveness of CAR-T therapy
Although CAR-T cells have revolutionized the treatment of hematological malignancies, there are several important factors that must be addressed regarding…
Date: 29th February 2024
Updates with the use of CAR-T therapy in ALL: ongoing challenges, strategies to overcome resistance & future outlooks
The treatment landscape of acute lymphoblastic leukemia (ALL) has transformed with the introduction of novel immunotherapeutic agents, including CAR-T cells…
Date: 22nd February 2024
Updates in lower- and higher-risk MDS: challenges, novel agents & key clinical trials at ASH 2023
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematologic neoplasms which can be categorized into lower- and higher-risk disease (LR-MDS;…
Date: 8th February 2024
Updates, challenges and novel agents being explored in BPDCN
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive and rare hematological malignancy associated with poor prognosis. Several challenges remain…
Date: 25th January 2024
Unanswered questions regarding the sequencing of BCMA therapies, the prognostic value of CTCs & the growing role of quadruplets
The treatment and management of patients with multiple myeloma is continually evolving, giving rise to novel prognostic tools and therapeutic…
Date: 18th January 2024
